Ni L, Tang R, Yuan C, Song K, Wang L, Zhang X, et al. Cinacalcet attenuated bone loss via inhibiting parathyroid hormone-induced endothelial-to-adipocyte transition in chronic kidney disease rats. Ann Transl Med. 2019;7:312 pubmed publisher

Krishnan V, Patel N, Mackrell J, Sweetana S, Bullock H, Ma Y, et al. Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients. Andrology. 2018;6:455-464 pubmed publisher

Jantarajit W, Lertsuwan K, Teerapornpuntakit J, Krishnamra N, Charoenphandhu N. CFTR-mediated anion secretion across intestinal epithelium-like Caco-2 monolayer under PTH stimulation is dependent on intermediate conductance K+ channels. Am J Physiol Cell Physiol. 2017;313:C118-C129 pubmed publisher

Wu M, Tang R, Liu H, Pan M, Liu B. Cinacalcet ameliorates aortic calcification in uremic rats via suppression of endothelial-to-mesenchymal transition. Acta Pharmacol Sin. 2016;37:1423-1431 pubmed publisher

Wu M, Zhang J, Tang R, Crowley S, Liu H, Lv L, et al. Elevated PTH induces endothelial-to-chondrogenic transition in aortic endothelial cells. Am J Physiol Renal Physiol. 2017;312:F436-F444 pubmed publisher

Teerapornpuntakit J, Wongdee K, Krishnamra N, Charoenphandhu N. Expression of osteoclastogenic factor transcripts in osteoblast-like UMR-106 cells after exposure to FGF-23 or FGF-23 combined with parathyroid hormone. Cell Biol Int. 2016;40:329-40 pubmed publisher

Bagi C, Berryman E, Zakur D, Wilkie D, Andresen C. Effect of antiresorptive and anabolic bone therapy on development of osteoarthritis in a posttraumatic rat model of OA. Arthritis Res Ther. 2015;17:315 pubmed publisher

Saeki M, Egusa H. [Novel strategies for the development of anabolic agents for treatment of osteoporosis]. Nihon Yakurigaku Zasshi. 2014;144:277-80 pubmed

Janovszky A, Vereb T, Szabo A, Piffkó J. [Current approaches for early detection and treatment of medication-related osteonecrosis of jaw]. Orv Hetil. 2014;155:1960-6 pubmed publisher

Lindahl K, Langdahl B, Ljunggren O, Kindmark A. Treatment of osteogenesis imperfecta in adults. Eur J Endocrinol. 2014;171:R79-90 pubmed publisher

Fazeli P, Wang I, Miller K, Herzog D, Misra M, Lee H, et al. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab. 2014;99:1322-9 pubmed publisher

McClung M, Grauer A, Boonen S, Bolognese M, Brown J, Diez Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412-20 pubmed publisher

Agholme F, Macias B, Hamang M, Lucchesi J, Adrian M, Kuhstoss S, et al. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. J Orthop Res. 2014;32:471-6 pubmed publisher

Tella S, Gallagher J. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155-70 pubmed publisher

Chanson P. [Not Available]. Rev Prat. 2013;63:924 pubmed

Markun S. [Combination therapy in postmenopausal osteoporosis leads to denser bones than monotherapy]. Praxis (Bern 1994). 2013;102:1203-4 pubmed publisher

Ueno M, Imura T, Inoue G, Takaso M. Posterior corrective fusion using a double-trajectory technique (cortical bone trajectory combined with traditional trajectory) for degenerative lumbar scoliosis with osteoporosis: technical note. J Neurosurg Spine. 2013;19:600-7 pubmed publisher

. Preliminary success with combination treatment for osteoporosis. BMJ. 2013;346:f3221 pubmed publisher

Eastell R, Walsh J. Is it time to combine osteoporosis therapies?. Lancet. 2013;382:5-7 pubmed publisher

Tsai J, Uihlein A, Lee H, Kumbhani R, Siwila Sackman E, McKay E, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382:50-6 pubmed publisher

Kang S, Deshpande S, Donneys A, Rodriguez J, Nelson N, Felice P, et al. Parathyroid hormone reverses radiation induced hypovascularity in a murine model of distraction osteogenesis. Bone. 2013;56:9-15 pubmed publisher

Zhang Y, Xu C, Lam H, Lee C, Li X. Protein chemical synthesis by serine and threonine ligation. Proc Natl Acad Sci U S A. 2013;110:6657-62 pubmed publisher

Saleh A, Hegde V, Potty A, Lane J. Bisphosphonate therapy and atypical fractures. Orthop Clin North Am. 2013;44:137-51 pubmed publisher

Warriner A, Saag K. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am. 2013;44:125-35 pubmed publisher

Cohen A, Stein E, Recker R, Lappe J, Dempster D, Zhou H, et al. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab. 2013;98:1971-81 pubmed publisher

Mitani Y. Effective treatment of a steroid-induced femoral neck fracture nonunion with a once-weekly administration of teriparatide in a rheumatoid patient: a case report. Arch Osteoporos. 2013;8:131 pubmed publisher

Thumbigere Math V, Gopalakrishnan R, Michalowicz B. Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw: a case report and narrative review. Northwest Dent. 2013;92:12-8 pubmed

Lampropoulou Adamidou K, Trovas G, Stathopoulos I, Papaioannou N. Case report: Teriparatide treatment in a case of severe pregnancy -and lactation- associated osteoporosis. Hormones (Athens). 2012;11:495-500 pubmed

Murphy D, Klein R, Smolen L, Klein T, Roberts S. Using common random numbers in health care cost-effectiveness simulation modeling. Health Serv Res. 2013;48:1508-25 pubmed publisher

Pietrogrande L, Raimondo E. Teriparatide in the treatment of non-unions: scientific and clinical evidences. Injury. 2013;44 Suppl 1:S54-7 pubmed publisher

Luigetti M, Capone F, Monforte M, Di Lazzaro V, DiLazzaro V. Muscle cramps and weakness after teriparatide therapy: a new drug-induced myopathy?. Muscle Nerve. 2013;47:615 pubmed publisher

Gesty Palmer D, Yuan L, Martin B, Wood W, Lee M, Janech M, et al. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol. 2013;27:296-314 pubmed publisher

Li Y, Li X, Bao C, Chen Q, Zhang H, Hu J. Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface. Osteoporos Int. 2013;24:1063-71 pubmed publisher

Hazel Fernandez L, Louder A, Foster S, Uribe C, Burge R. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study. BMC Musculoskelet Disord. 2013;14:4 pubmed publisher

Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin. 2013;29:195-203 pubmed publisher

Lindsay R, Zhou H, Cosman F, Nieves J, Dempster D. Double and quadruple tetracycline labeling of bone: impact of the label itself. J Bone Miner Res. 2013;28:222-3 pubmed publisher

Nieves J, Mosner M, Silverstein S. Osteoporosis. N Y State Dent J. 2012;78:30-5 pubmed

Ohbayashi Y, Miyake M, Sawai F, Minami Y, Iwasaki A, Matsui Y. Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:e31-7 pubmed publisher

Corrigan R, Miller A, McNally M, Javaid M. Treatment of fracture non-union in a young adult with combination anabolic and anti-resorptive bone therapy. Rheumatology (Oxford). 2013;52:1147-9 pubmed publisher

Uelbelhart B, Rizzoli R. [Osteoporosis]. Rev Med Suisse. 2012;8:109-10, 112-5 pubmed

Cipriani C, Capriani C, Irani D, Bilezikian J. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012;27:2419-28 pubmed publisher

Theodorou S, Theodorou D, Kakitsubata Y, Adams J. Low bone mass in Ehlers-Danlos syndrome. Intern Med. 2012;51:3225-6 pubmed

Yamamoto T, Tsujimoto M, Hamaya E, Sowa H. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 ?g/day administered subcutaneously in Japanese patients with osteoporosis. J Bone Miner Metab. 2013;31:199-205 pubmed publisher

Mokuda S, Sawada N, Matoba K, Yamada A, Onishi M, Okuda Y, et al. Serum undercarboxylated osteocalcin level increases with 48 weeks of teriparatide treatment in pre-treated elderly rheumatoid arthritis patients who use anti-resorptive drugs. J Endocrinol Invest. 2012;35:796-9 pubmed

Murphy D, Smolen L, Klein T, Klein R. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord. 2012;13:213 pubmed publisher

Shiraki M, Sugimoto T, Nakamura T. Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women. Osteoporos Int. 2013;24:219-26 pubmed publisher